← All trials
NCT05427396
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 9, 2022
- Primary completion
- Aug 31, 2024
- Completion date
- Aug 31, 2025
- First posted
- Jun 22, 2022
- Last posted
- Sep 22, 2022
- Enrollment
- 198
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Junshi Bioscience Co.,Ltd.Lead sponsor
- Sponsor GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.